Last reviewed · How we verify

FAP IL2V — Competitive Intelligence Brief

FAP IL2V (FAP IL2V) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody-cytokine fusion. Area: Oncology.

phase 3 Bispecific antibody-cytokine fusion FAP (fibroblast activation protein) and IL-2 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FAP IL2V (FAP IL2V) — Hoffmann-La Roche. FAP IL2V is a bispecific immunotherapy that targets fibroblast activation protein (FAP) on cancer-associated fibroblasts while delivering interleukin-2 (IL-2) to activate anti-tumor immune responses.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FAP IL2V TARGET FAP IL2V Hoffmann-La Roche phase 3 Bispecific antibody-cytokine fusion FAP (fibroblast activation protein) and IL-2 receptor
L19IL2 + L19TNF L19IL2 + L19TNF Philogen S.p.A. phase 3 Bispecific antibody-cytokine fusion Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody-cytokine fusion class)

  1. Hoffmann-La Roche · 1 drug in this class
  2. Philogen S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FAP IL2V — Competitive Intelligence Brief. https://druglandscape.com/ci/fap-il2v. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: